{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:41:10Z","timestamp":1793677270359,"version":"4.5.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s11912-024-01571-0","type":"journal-article","created":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T05:24:26Z","timestamp":1719897866000},"page":"1113-1119","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Clinical Issue of Myasthenia Gravis Related to Immune Checkpoint Inhibitors"],"prefix":"10.1007","volume":"26","author":[{"given":"Kyoichi","family":"Kaira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuto","family":"Mouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ou","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kagamu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"key":"1571_CR1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/jcph.2187","volume":"63","author":"T Niimura","year":"2023","unstructured":"Niimura T, et al. Characterization of immune checkpoint inhibitor-induced myasthenia gravis using the US Food and Drug Administration Adverse Event Reporting System. J Clin Pharmacol. 2023;63:473\u20139.","journal-title":"J Clin Pharmacol"},{"key":"1571_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10637-023-01347-6","volume":"41","author":"C Wang","year":"2023","unstructured":"\u2022\u2022 Wang C, et al. Clinical characteristics, treatment, and outcome of nivolumab-induced myasthenia gravis. Invest New Drugs. 2023;41:333\u20139. This study collected case reports, reviews, case series and clinical studies for nivolumab-induced myasthenia gravis and summarized the clinical features and treatment.","journal-title":"Invest New Drugs"},{"key":"1571_CR3","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","volume":"7","author":"H Safa","year":"2019","unstructured":"\u2022\u2022 Safa H, et al. Immune checkpoint inhibitor-related myasthenia gravis: single-center experience and systematic review of the literature. J ImmunoTherapy Cancer. 2019;7:319. This study compared between single-center patients and previously reported case series about the clinical demographics, management and outcome of ICI-induced MG.","journal-title":"J ImmunoTherapy Cancer"},{"key":"1571_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1093\/cei\/uxac108","volume":"211","author":"S Zhao","year":"2023","unstructured":"\u2022 Zhao S, et al. Clinical features, diagnosis, and management of pembrolizumab-induced myasthenia gravis. Clin Exp Immunol. 2023;211:85\u201392. The Chinese databases described the diagnosis and management of pembrolizumab-induced myasthenia gravis.","journal-title":"Clin Exp Immunol"},{"key":"1571_CR5","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3389\/fneur.2020.00634","volume":"11","author":"YT Huang","year":"2020","unstructured":"Huang YT, et al. Immune checkpoint inhibitor-induced myasthenia gravis. Front Neurol. 2020;11:634.","journal-title":"Front Neurol"},{"key":"1571_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/acn3.51761","volume":"10","author":"G Masi","year":"2023","unstructured":"Masi G, et al. Clinicoserological insights into patients with immune checkpoint inhibitor-induced myasthenia gravis. Ann Clin Transl Neurol. 2023;10:825\u201331.","journal-title":"Ann Clin Transl Neurol"},{"key":"1571_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","volume":"82","author":"D Makarious","year":"2017","unstructured":"Makarious D, Horwood K, Coward JIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017;82:128\u201336. This study firstly reported the clinical characteristic of ICI-induced myasthenia gravis, collecting previously reported case series.","journal-title":"Eur J Cancer"},{"key":"1571_CR8","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00520-023-07987-x","volume":"31","author":"JMJ Weaver","year":"2023","unstructured":"Weaver JMJ, et al. Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor-induced myasthenia gravis, myocarditis, and myositis: a case series. Support Care Cancer. 2023;31:518.","journal-title":"Support Care Cancer"},{"key":"1571_CR9","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1002\/mus.28037","volume":"69","author":"S Zadeh","year":"2024","unstructured":"Zadeh S, et al. Novel uses of complement inhibitors in myasthenia gravis: two case reports. Muscle Nerve. 2024;69:368\u201372.","journal-title":"Muscle Nerve"},{"key":"1571_CR10","first-page":"e45455","volume":"15","author":"T Kosick","year":"2023","unstructured":"Kosick T, et al. A case of pembrolizumab-induced myasthenia gravis. Cureus. 2023;15:e45455.","journal-title":"Cureus"},{"key":"1571_CR11","doi-asserted-by":"publisher","first-page":"e005970","DOI":"10.1136\/jitc-2022-005970","volume":"10","author":"W Gao","year":"2022","unstructured":"Gao W, et al. Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis. J Immunother Cancer. 2022;10:e005970.","journal-title":"J Immunother Cancer"},{"key":"1571_CR12","doi-asserted-by":"publisher","first-page":"5611","DOI":"10.3390\/jcm11195611","volume":"11","author":"F Deharo","year":"2022","unstructured":"Deharo F, et al. Immune checkpoint inhibitor-induced myositis\/myocarditis with myasthenia gravis-like misleading presentation: a case series in intensive care unit. J Clin Med. 2022;11:5611.","journal-title":"J Clin Med"},{"key":"1571_CR13","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.2169\/internalmedicine.8554-21","volume":"61","author":"Y Oshima","year":"2022","unstructured":"Oshima Y, Fujii S, Horiuchi K. Pembrolizumab-induced myasthenia gravis relapse after immunosuppressive therapy. Intern Med. 2022;61:3281\u20135.","journal-title":"Intern Med"},{"key":"1571_CR14","first-page":"e16337","volume":"13","author":"N Verma","year":"2021","unstructured":"Verma N, et al. Rituximab for immune checkpoint inhibitor myasthenia gravis. Cureus. 2021;13:e16337.","journal-title":"Cureus"},{"key":"1571_CR15","doi-asserted-by":"publisher","first-page":"682262","DOI":"10.3389\/fimmu.2021.682262","volume":"12","author":"S Liamg","year":"2021","unstructured":"Liamg S, et al. Immune myocarditis overlapping with myasthenia gravis due to anti-PD-1 treatment for a chordoma patient: a case report and literature review. Front Immunol. 2021;12:682262.","journal-title":"Front Immunol"},{"key":"1571_CR16","first-page":"e16316","volume":"13","author":"C Heleno","year":"2021","unstructured":"Heleno C, et al. Myasthenia gravis as an immune-mediated side effect of checkpoint inhibitors. Cureus. 2021;13:e16316.","journal-title":"Cureus"},{"key":"1571_CR17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ajem.2021.03.005","volume":"46","author":"DN Lie","year":"2021","unstructured":"Lie DN, et al. Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome. Am J Emerg Med. 2021;46:51\u20135.","journal-title":"Am J Emerg Med"},{"key":"1571_CR18","first-page":"101105","volume":"29","author":"S Nakanishi","year":"2020","unstructured":"Nakanishi S, et al. A case report of nivolumab-induced myasthenia gravis and myositis in a metastatic renal cell carcinoma patient. Uro Case Rep. 2020;29:101105.","journal-title":"Uro Case Rep"},{"key":"1571_CR19","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2020","unstructured":"Narayanaswami P, et al. International Consensus Guidance for management of myasthenia gravis: 2020 update. Neurology. 2020;96:114\u201322.","journal-title":"Neurology"},{"key":"1571_CR20","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1002\/cam4.5050","volume":"12","author":"J Longinow","year":"2023","unstructured":"\u2022 Longinow J, et al. Immune checkpoint inhibitor-induced myocarditis, myasthenia gravis, and myositis: a single-center case series. Cancer Med. 2023;12:2281\u20139. This study describes the clinical feature of small sample size with overlapping syndrome of ICI-induced myocarditis, myasthenia gravis and myositis, and reports the mortality and possible predictor of overlap syndrome.","journal-title":"Cancer Med"},{"key":"1571_CR21","doi-asserted-by":"publisher","first-page":"e000028","DOI":"10.1136\/bmjno-2019-000028","volume":"2","author":"CS Phua","year":"2020","unstructured":"Phua CS, et al. Myasthenia gravis and concurrent myositis following PD-L1 checkpoint inhibitor for non-small cell lung cancer. BMJ Neurol Open. 2020;2:e000028.","journal-title":"BMJ Neurol Open"},{"key":"1571_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.25259\/JNRP_10_2022","volume":"14","author":"Z \u00dcnl\u00fct\u00fcrk","year":"2023","unstructured":"\u00dcnl\u00fct\u00fcrk Z, et al. Myocarditis-myositis-myasthenia gravis overlap syndrome depending on immune checkpoint inhibitor. J Neuro Rural Pract. 2023;14:143\u20134.","journal-title":"J Neuro Rural Pract"},{"key":"1571_CR23","doi-asserted-by":"publisher","first-page":"950801","DOI":"10.3389\/fmed.2022.950801","volume":"9","author":"B Yin","year":"2022","unstructured":"Yin B, et al. Myocarditis and myositis\/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: a case report and review of the literature. Front Med. 2022;9:950801.","journal-title":"Front Med"},{"key":"1571_CR24","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/onco.13931","volume":"26","author":"R Pathak","year":"2021","unstructured":"\u2022 Pathak R, et al. Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist. 2021;26:1052\u201361. This study focus on the management and outcome of ICI-induced overlap syndrome by analyzing previously reported case series and clinical study.","journal-title":"Oncologist"},{"key":"1571_CR25","doi-asserted-by":"publisher","first-page":"e005970","DOI":"10.1136\/jitc-2022-005970","volume":"10","author":"W Gao","year":"2022","unstructured":"Gao W, et al. Rechallenge of immune checkpoint inhibitors in case with adverse events including myasthenia gravis. J ImmuoTherapy Cancer. 2022;10:e005970.","journal-title":"J ImmuoTherapy Cancer"},{"key":"1571_CR26","doi-asserted-by":"publisher","first-page":"6159","DOI":"10.1007\/s00520-020-05710-8","volume":"28","author":"ME Suarez-Almazor","year":"2020","unstructured":"Suarez-Almazor ME, et al. The Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. Support Care Cancer. 2020;28:6159\u201373.","journal-title":"Support Care Cancer"},{"key":"1571_CR27","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, et al. International consensus guidance for management of myasthenia gravis: 2020 update. Neurology. 2021;96:114\u201322.","journal-title":"Neurology"},{"key":"1571_CR28","doi-asserted-by":"publisher","first-page":"424","DOI":"10.14740\/jmc3783","volume":"12","author":"N Tahir","year":"2021","unstructured":"Tahir N, et al. Nivolumab, a double-edged Sword: a case report of nivolumab-induced myasthenia gravis. J Med Cases. 2021;12:424\u20138.","journal-title":"J Med Cases"},{"key":"1571_CR29","doi-asserted-by":"publisher","first-page":"2593","DOI":"10.2217\/fon-2020-0861","volume":"17","author":"K Shimozaki","year":"2021","unstructured":"Shimozaki K, et al. Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data. Future Oncol. 2021;17:2593\u2013603.","journal-title":"Future Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-024-01571-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-024-01571-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-024-01571-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T01:03:54Z","timestamp":1726967034000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-024-01571-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1571"],"URL":"https:\/\/doi.org\/10.1007\/s11912-024-01571-0","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,1]]},"assertion":[{"value":"18 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving human participants performed in this study adhered to the ethical standards of the institutional and\/or national research committees and the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interest"}}]}}